{"prompt": "['Product: MK-3475', '140', 'Protocol/Amendment No.: 604-09', '9. Reporting of Future Biomedical Research Data to Subjects', 'No information obtained from exploratory laboratory studies will be reported to the', 'subject, family, or physicians. Principle reasons not to inform or return results to the', 'subject include: Lack of relevance to subject health, limitations of predictive capability,', 'and concerns regarding misinterpretation.', 'If important research findings are discovered, the Sponsor may publish results, present', 'results in national meetings, and make results accessible on a public website in order to', 'rapidly report this information to doctors and subjects. Subjects will not be identified by', 'name in any published reports about this study or in any other scientific publication or', 'presentation.', '10. Future Biomedical Research Study Population', 'Every effort will be made to recruit all subjects diagnosed and treated on Sponsor clinical', 'trials for Future Biomedical Research.', '11. Risks Versus Benefits of Future Biomedical Research', 'For future biomedical research, risks to the subject have been minimized. Risks include', 'those associated with venipuncture to obtain the whole blood specimen. This specimen', 'will be obtained at the time of routine blood specimens drawn in the main trial.', 'The Sponsor has developed strict security, policies and procedures to address subject data', 'privacy concerns. Data privacy risks are largely limited to rare situations involving', 'possible breach of confidentiality. In this highly unlikely situation there is risk that the', 'information, like all medical information, may be misused.', '12. Questions', 'Any questions related to the future biomedical research should be e-mailed directly to', '  clinical.specimen.management@merck.com.', '13. References', '1. National Cancer Institute: http://www.cancer.gov/dictionary/?searchTxt=biomarker', '2. International Conference on Harmonization: Definitions for Genomic Biomarkers,', 'Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding', 'Categories - E15; http://www.ich.org/LOB/media/MEDIA3383.pdf', '3. Industry Pharmacogenomics Working Group. Understanding the Intent, Scope and', 'Public Health Benefits of Exploratory Biomarker Research: A Guide for IRBs/IECs', 'and Investigational Site Staff. Available at http://i-pwg.org/', '4. Industry Pharmacogenomics Working Group. Pharmacogenomics Informational', 'Brochure for IRBs/IECs and Investigational Site Staff. Available at http://i-pwg.org/', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '141', 'Protocol/Amendment No.: 604-09', '12.3 ECOG Performance Status', 'Grade', 'Description', '0', 'Normal activity. Fully active, able to carry on all pre-disease', 'performance without restriction.', 'Symptoms, but ambulatory. Restricted in physically strenuous', '1', 'activity, but ambulatory and able to carry out work of a light or', 'sedentary nature (e.g., light housework, office work).', 'In bed <50% of the time. Ambulatory and capable of all self-care,', '2', 'but unable to carry out any work activities. Up and about more than', '50% of waking hours.', 'In bed >50% of the time. Capable of only limited self-care, confined', '3', 'to bed or chair more than 50% of waking hours.', '4', '100% bedridden. Completely disabled. Cannot carry on any self-', 'care. Totally confined to bed or chair.', '5', 'Dead.', '* As published in Am. J. Clin. Oncol.: Oken MM, Creech RH, Tormey DC, Horton J, Davis TE,', 'McFadden ET, Carbone PP: Toxicity And Response Criteria Of The Eastern Cooperative Oncology', 'Group. Am J Clin Oncol. 1982;5:649-655. The Eastern Cooperative Oncology Group, Robert Comis', 'M.D., Group Chair.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}